Impact of age and co-morbidities in patients with newly diagnosed glioblastoma: a pooled data analysis of three prospective mono-institutional phase II studies
| Autor: | Giovanna Mantini, Silvia Chiesa, Vincenzo Valentini, Carmelo Anile, Gabriella Colicchio, Giuseppe D'Agostino, Annunziato Mangiola, Mario Balducci, Berardino De Bari, Alessio G. Morganti, Alba Fiorentino, Maria Antonietta Gambacorta, Pasquale De Bonis, Vincenzo Frascino, Francesco Miccichè, Gian Carlo Mattiucci, Stefania Manfrida |
|---|---|
| Přispěvatelé: | Balducci M, Fiorentino A, De Bonis P, Chiesa S, Manfrida S, D'Agostino GR, Mantini G, Frascino V, Mattiucci GC, De Bari B, Mangiola A, Miccichè F, Gambacorta MA, Colicchio G, Morganti AG, Anile C, Valentini V |
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty medicine.medical_treatment Co-morbidity Antineoplastic Agents Comorbidity Kaplan-Meier Estimate Radiosurgery Disease-Free Survival NO Young Adult Elderly Internal medicine medicine Temozolomide 80 and over Humans Young adult Survival analysis Aged Aged 80 and over Performance status Radiotherapy business.industry Brain Neoplasms Age Factors Hematology General Medicine Middle Aged medicine.disease Combined Modality Therapy Surgery Clinical trial Radiation therapy Dacarbazine Chemoradiation Concomitant Female business Glioblastoma medicine.drug |
| Popis: | To analyse the impact of age and co-morbidities on compliance and outcomes in GBM patients enrolled in three prospective phase II trials. GBM patients (≥ 18 years) were treated with radiotherapy (60 Gy) or enrolled in a Fractionated Stereotactic Conformal-Radiotherapy Phase II trial (69.4 Gy). Concomitant and adjuvant chemotherapy with Temozolomide (TMZ) was administered. Charlson Index Co-morbidity (CCI) was used to assess co-morbidity. Toxicity was evaluated according to RTOG score. Survival analysis was performed by the Kaplan-Maier. Influence of age and co-morbidity was evaluated using log-rank test. From 2001 to 2008, 146 patients were enrolled: 56 (38.4 %) aged over 65 and 90 under 65. CCI ≥ 1 was observed in 41 % of elderly and 22 % of young group. Patients' compliance was 97.9 % for radio-chemotherapy. Acute toxicity was mild with no difference between the groups. Global median progression-free survival (PFS) and overall survival (OS) were 12 and 18 months, respectively. Age, surgery and radiation dose correlated with survival (p = 0.01, p = 0.04 and p = 0.03). CCI ≤ 2 did not show any influence on OS. Our data show that elderly with a good performance status and few co-morbidity may be treated as younger patients; moreover, age confirms a negative impact on survival while CCI ≤ 2 did not correlated with OS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|